Forum Topics CSL CSL 1H FY26 results

Pinned straw:

Added 4 weeks ago

I never thought CSL would be a basket case business I would need to worry about. There’s a lot that’s been dumped on shareholders in the space of 16 hours. There’s a lot to digest here. I’m not sure I like my capital being used to buy back shares either. I would rather a larger dividend so I could use the capital elsewhere, like another business, perhaps Wisetech or PME? One with superior ROE and growth prospects. What are others making of these write downs and the 81% drop in reported NPAT!

CSL Limited (CSL) has released its half-year results for the period ending 31 December 2025:

  • Total revenue: $8.3 billion, down 4%

  • NPATA excluding restructuring costs and impairments: $1.9 billion, down 7%

  • Reported NPAT: $401 million, down 81%

  • Cash flow from operations: $1.3 billion, up 3%

  • Interim dividend: $1.30 per share

  • Share buy-back expanded from $500 million to $750 million

  • FY26 guidance: 2-3% revenue growth and 4-7% NPATA growth, excluding one-off costs

  • Record date for interim dividend: 11 March 2026

  • Payment date for interim dividend: 9 April 2026
UlladullaDave
Added 4 weeks ago

Quite interesting to see how hard retail went into CSL over the last year or so as the price fell. Especially on those big gap downs.


This has been such a high quality business for so long it is unsurprising.



a0004b5a68775a2b98aa0a5a2961d6319183fa.png

16

mikebrisy
Added 4 weeks ago

@UlladullaDave I think that last leg up on the light blue line might have been me.

15
lankypom
Added 4 weeks ago

Fantastic coverage of the CSL developments here on Strawman - I'm finding it more insightful than reading the AFR.

I've held CSL for nearly 14 years in my SMSF, returns have been positive but pitiful 3.5% pa, well below the target 10% annual return I set for all my holdings. As of 5 minutes ago I am no longer a shareholder - as others have pointed out, there are many rich pickings on offer in the market right now, and the prospect of meaningful growth (and share price recovery) in CSL is several years off, so it's time to move on.

23
Solvetheriddle
Added 4 weeks ago

Ok so we have some more explanation. I am not going to write a full report here, ill do that later. Writedowns, to be expected, weakness in various operations, to be expected. ill even accept the albumin swings. ill talk about the two areas that surprised me. Firstly, the issues in IG, from what i can recall, this is the first time CSL are coming clean with the story at Behring, and i do feel led down the garden path here. Strength in Behring is the reason i persisted in holding CSL. There were a couple of questions aimed straight at the inconsistency, if IG is such a strong market, as CSL said only at their investor day last year, and use terms like limited supply, but now we see, terms like well balanced market, and CSL needs to put more marketing and sales people on the ground to hold share and adjust its appraoch to tenders, where it appears CSL has been gamed. sounds inconsistent, and poor execution is about the best you can say about it.

The other surprise is keeping guidance, so profit falls in FH goes to profit growth of (ok only +4-7%) for the full year. CSL did provide a bridge from FH to full year with various inititaes and they have done well on cost out, and they point to positive initial momentum here, that guidance could be optimistic, as we have seen before, especially if it is based on share gains.

CSL is now priced for very low growth, but the profit growth is also low. luckily we live in a relative value world where there have been many stocks growing profitability strongly and sold down because of AI fears. ill lighten into CSL, and look to buy the saas, platforms, even insurance brokers (heaven forbid where will the fear end!!) if CSL can maintain guidance that will be a positive and i will reass.

25

mikebrisy
Added 4 weeks ago

@Solvetheriddle you nailed it, IMHO, it's about relative valuation.

And as I am strongly in the camp that believes that AI will not blow up everything, I see a lot of opportunity relative to holding $CSL.

18
Goldfish
Added 4 weeks ago

Disappointing, but not a disaster (to me at least). Definitely not a time to sell IMO

The current half was obviously poor, with both revenue and profits down from PCP. Interestingly, full year guidance is much more positive. In order to achieve "2-3% growth in revenue and 4-7% growth in NPATA" for the full year, they will require a big turn around in the second half (obviously). The market clearly doubts they will be able to do it

With the current share price ($151), if they meet the mid-point of their guidance for the full year, they would be on a PE of 16. For me, this is the single most important fact to keep in mind. A lot of the stuff people are saying about CSL would be a lot more relevant if the PE was still over 40. At a PE of 16, you are not paying for perfection or high growth.

Lots of people are putting the boot into CSL today. Perhaps some criticisms of management are valid. I feel like people are comparing to the "glory" days, when CSL was a rapid growth company.

My argument would be that yes, CSL is no longer a rapid-growth company. This was always going to happen as it increased in size and market cap. However, it is no longer priced as a rapid-growth company. On a PE of 16, with a dividend-yield of well over 2%, CSL is well-priced for what it is likely to deliver over the long-term: solid high-single digit growth.

I like that they have increased the buy-back and maintained the dividend.

I would much rather own CSL at a PE of 16 than Coles at a PE of 26. Yes Coles pay a higher (franked) dividend, but CSL are ploughing back two thirds of their profits into research. Sooner or later, some of that will pay off

This episode makes me think back to one of Strawman's blog posts about conviction. I feel like this is a perfect example. Because I have a pretty good understanding (I think) of the company and high conviction, I can look through this current weakness and avoid panic


23

Strawman
Added 4 weeks ago

I may have got my sums wrong @Goldfish

I took last year's NPATA 0f $3,303m, grow that by 7% to get $3534m. Divide that by 485 million shares on issue and i get a FY2026 EPS (ex Amortisation) of ~7.30.

At a $160 share price, that's a forward PE of over 21.

If i've missed something, and the PE is indeed 16x, that would very much change my perspective.

20

Goldfish
Added 4 weeks ago

@Strawman

My calculations were:

Net profit 2025FY $3,002 million USD

Multiplied by mid-point of guidance (5.5%) = $3167 USD

Converted into AUD = $4475 million

Market cap at share price $151 = $73.137 billion

PE = 16.4


[since starting these posts, the share price is up to $161. Sommeone agrees with me, at least]

19

Strawman
Added 4 weeks ago

ugh... of course. What a rookie error!! Thanks @Goldfish

Ok, I take back what I said. Shares DO seem cheap!

17

PhilO
Added 4 weeks ago

I got a sense of overwhelm trying to digest this result before coffee this morning. I should never do that. But reflecting on it after my first coffee, the most consequential and unexpected development to the largest part of the business (blood plasma) seems to be regulatory changes in the US and China impacting pricing and marginal demand for plasma products.

The large one off restructuring and impairment charges were largely known about.

So the key issue for me, having bought CSL for the blood plasma division (viewing the rest as a sideshow) was whether these regulatory changes alter the long term earnings power of the plasma division, or simply change the path of earnings over the next few years. Thinking it’s the later. PE looks low. I’m holding.

18

mikebrisy
Added 4 weeks ago

Alternatively, if you look at the consensus for FY26 (which it looks like they might get close to) of US$2.584bn (prior to today's impairments) at $0.70 USD to AUD and SOI of 482m, then at a SP of A$160, I get:

A$160 / (US$2584m / 0.7 / 482m) = P/E = 21

Now that is before-today's impairments, which, while non-cash, point to a loss in the future earnings power of affected portfolio items. And sure, the FY26 consensus bakes in "one-off" restructuring charges. But are these really one-off, with the prospect of two CEOs cycling through in as many years, and likely some Board and next level Executive churn too?

Add the management turmoil, the restructuring in train, and the reason that the Board has such concerns about the growth portfolio that it was one of the reasons for firing - sorry, retiring - the CEO.

I therefore question: does a forward P/E of 21 properly compensate for those risks and external headwinds?

Let's remember that pharma companies attain P/Es of 25-30 when they have well-regarded development portfolios. $CSL is not in that place.

FY26 forward P/Es for selected global pharma companies:

$AZN=25; $NVS=21; $GSK=14; $MRK=27; $RO=18; $NVO=15; $LLY=31 (GLP-1 outlier) to name a few.

All these are suffering P/E depression due to US market headwinds.

I'm not judging $CSL on past glory, but trying to read the current reality and its industry context. (Part of what worried me about McNamee's address last night was that his confidence sounded more ground in the $CSL of yesteryear, than the $CSL of today. The past is behind us. Valuation is about the future.)

21

Tom73
Added 4 weeks ago

Well it looks like we almost have a market here on SM, sellers, holders and I am sure many tempted buyers – I had a buy order in briefly at $140 in case it cracked below $150 to what I saw as good value (@Goldfish ) even with all the warts that have been called out (@mikebrisy ).

I only have a half position in CSL so had capacity to add, but the thing that held me off chasing the price as it rose from $150 was the write-downs and leadership. The underlying business is ok, it could be good like it was but at the current price it just has to be ok.

So the issue I have is the write-downs and leadership are very related. Normally when you get a new CEO, you expect a big clean out, lots of write downs as they clear the deck, reset the base for them to become the Hero of recovery.

Not this time, the hit taken looks light and only enough to keep a positive NPAT result (there is still US$24.4b in PPE, ROU & Intangibles on the balance sheet). I guess that is because the incoming CEO had nothing to do with it and given the temporary nature it is questionable how much he will push to cut deep to take out any remaining issues. The call this time was made by the board (McNamee chiefly) and it’s depth possibly limited to maintaining their positions/credibility given their tenure over the period being corrected. 

Now I will also have to confess to having a lot of faith in Gordon Naylor, partly due to personal interactions but also due to his track record and his nature. He appears and sounds very laid back but listens deeply and has a detailed engineers approach to problems solving and planning. Despite only have a temporary role, he is starting with a lot of runs on the board and a deep understanding of the business, so can genuinely hit the ground running.

So I see a silver lining in the horror scenario laid out by @mikebrisy of there also being board changes and a likely CEO change. I think they can do this full reset with Gordon holding the wheel through it, it needs to happen.

I would say most of the pain is priced in, but if as I suspect the market will lose it’s shit if there are more write off’s in a year or two on a permeant CEO appointment (Gordon or other). The price is likely to get smashed. So I am holding off on any additional investment in CSL until this is resolved. If the price drops to $140 or below I will probably top up, if not, I am fine sitting on a half position and using the money elsewhere.

Disc: I own RL

18

PhilO
Added 4 weeks ago

Hi @mikebrisy I look at the PE as mainly representative of the majority blood plasma division, which

  • represents approximately 60% of revenues and 80% of current profits,
  • is moaty and really should trade at a premium in my view.

The rest probably doesn’t deserve a high PE. My logic was always to buy CSL at a price that makes sense for the blood plasma division alone, with the rest a free option.

18